Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -210.83% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -34.87
2
The company has declared Negative results for the last 4 consecutive quarters
3
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.79%
0%
-18.79%
6 Months
29.66%
0%
29.66%
1 Year
63.12%
0%
63.12%
2 Years
-5.05%
0%
-5.05%
3 Years
-7.62%
0%
-7.62%
4 Years
-68.46%
0%
-68.46%
5 Years
-63.5%
0%
-63.5%
Inventiva SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.48%
EBIT Growth (5y)
-210.83%
EBIT to Interest (avg)
-34.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.44
Sales to Capital Employed (avg)
-1.03
Tax Ratio
2.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-67.22
EV to EBIT
-5.57
EV to EBITDA
-5.76
EV to Capital Employed
-7.58
EV to Sales
41.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
9.20
17.50
-47.43%
Operating Profit (PBDIT) excl Other Income
-95.90
-105.50
9.10%
Interest
12.20
5.20
134.62%
Exceptional Items
-79.40
-0.40
-19,750.00%
Consolidate Net Profit
-184.20
-110.40
-66.85%
Operating Profit Margin (Excl OI)
-10,814.90%
-6,180.00%
-463.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -47.43% vs 43.44% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -66.85% vs -103.31% in Dec 2023
About Inventiva SA 
Inventiva SA
Pharmaceuticals & Biotechnology
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Coordinates 
Company Details
50 rue de Dijon, Daix , DAIX None : 21121
Registrar Details






